Nodality, Inc. Announces Expansion of Company's Patent Estate Covering Programs to Improve the Treatment of Patients with Severe Diseases in Immunology, Oncology, and Autoimmune Diseases

Nodality, Inc., a next-generation life sciences company partnering with leading firms to advance precision medicine, announced today the issuance by the United States Patent and Trademark Office (USPTO) of Patent Number 8,394,599, which broadly covers methods for applying the Company's Single Cell Network Profiling (SCNP) technology. SCNP provides the core foundation for Nodality's programs dedicated to making medicines better by increasing the productivity of therapeutic R&D programs, enhancing life cycle management for commercialized drugs, and introducing new predictive diagnostics. With the issuance of this patent, Nodality now owns or has exclusive rights to more than 25 issued patents and 80 patent applications.

Laura Brege, President and Chief Executive Officer, commented, “The new patent extends and complements Nodality's other foundational patents covering SCNP, a uniquely powerful tool for correlating clinical data with functional biology. The patent provides further protection for unique biomarkers of protein activation and cell function in single cells and, importantly, applications of this information in clinical management and therapeutic product development. Through our growing patent estate and partnered programs, Nodality is in a key position to improve the treatment of patients with severe diseases, including in immunology, oncology, and autoimmune diseases.”

About Nodality

Nodality is a next-generation life sciences company that is advancing drug discovery, therapeutic development, and precision medicine by delivering critical and clinically actionable information to reveal biology, define disease, and improve health. Nodality's unique, innovative, and proprietary platform, Single Cell Network Profiling or SCNP, enables the promise of precision medicine by unlocking the potential of therapeutics and by matching therapies with the right patients. SCNP enables functional characterization of disease-associated signaling at the individual patient level, enabling optimization of treatment tailored to target the biology driving the disease. Nodality is applying SCNP to develop molecular diagnostics to improve clinical decision-making in cancer and autoimmune diseases, with the lead products targeting treatment management in hematological malignancies. Nodality is also collaborating with Pharma partners on patient stratification & companion diagnostics development, drug & disease profiling, determination of mechanism of action, mechanism-based competitive differentiation, whole blood PD assays, and biomarker discovery & development. These applications can result in increased probability of success, reduced timeline for clinical development, and differentiation from competitors in the marketplace. Nodality established multi-year pharma strategic collaborations with UCB Pharma S.A. (Euronext Brussels: UCB) and Pfizer (NYSE: PFE) in 2012, utilizing its SCNP technology to assist the development of several compounds focusing initially on immunology disorders.

About Single Cell Network Profiling

Single Cell Network Profiling (SCNP) is a proprietary technology licensed from Stanford University to characterize cell signaling networks in immunology and cancer. SCNP, by measuring functional signaling network behavior at the level of the single cell, has several advantages over other currently used molecular technologies. These include unprecedented insight into the presence and clinical meaning of functional cellular heterogeneity in otherwise molecularly and phenotypically homogeneous tissues, including the identification of rare cell subsets such as drug-resistant and stem cells. As such, the technology has widespread application in preclinical drug development, clinical drug development and diagnostic development.